Jessica Rajan, MD
Allergy & Immunology · Bellaire, TXNPI 1811127848
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2021 at $727 and has fallen 62.4% since, to $274 in 2025. That places this record below the midpoint for allergy & immunology clinicians in TX, where the typical reported total is $5,878.
Across 176 payments — averaging $19.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$896
- GSK$466
- Kaleo, Inc.$404
- Regeneron Healthcare Solutions, Inc.$328
- Sanofi$176
- Pfizer$175
- plus $903 from 15 others
What the payments were for
- Food & beverage$3,30899%
- Education$401%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $896 |
| GSK | 29 | $466 |
| Kaleo, Inc. | 20 | $404 |
| Regeneron Healthcare Solutions, Inc. | 10 | $328 |
| Sanofi | 9 | $176 |
| Pfizer | 9 | $175 |
| Alk-abello, Inc | 12 | $164 |
| ARS Pharmaceuticals Operations, Inc. | 7 | $148 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $113 |
| Grifols USA, LLC | 5 | $87 |
| Shire North American Group Inc | 4 | $84 |
| Genentech USA, Inc. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 2 | $44 |
| Optinose US, Inc. | 2 | $38 |
| Novartis | 2 | $35 |
| Octapharma USA, Inc. | 2 | $32 |
| Pharming Healthcare, Inc. | 1 | $24 |
| LEO Pharma Inc. | 1 | $22 |
| Covis Pharma GmbH | 1 | $19 |
| Cycle Pharmaceuticals Inc | 1 | $17 |
| Incyte Corporation | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$125
How this compares
$3,348 in reported general payments places this provider in the 35th percentile of 336 allergy & immunology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levocetirizine Dihydrochloride | 15 | $127 |
Paid to pharmacies, not to this prescriber.
Other allergy & immunology in Bellaire
- Serge de GolovineBellaire$125K
- Aries GavinoBellaire$124K
- Dat TranBellaire$35K
- Joseph DiazSan Antonio$1.1M
- Richard WassermanDallas$452K
- Matthew FeldmanDallas$410K
- Lukena KarkhanisSan Antonio$377K
- Paul VigoAustin$304K
- Neha ReshamwalaAustin$303K
- Lara GrossDallas$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.